September 23, 2020
Sibofimloc (EB8018/TAK-018) is a first-in-class, orally administered, gut-restricted small molecule designed to reduce inflammation underlying Crohn’s disease Sibofimloc binds FimH, a novel microbiome-derived therapeutic target validated by Enterome, to selectively disarm virulent bacteria in the gut that can cause inflammation without disrupting the local microbiome Sibofimloc is advancing through clinical development under a global licensing,...


90 million to 18 Talented Researchers
19. October 2020
Søren Dinesen Lumdbeckfonden
Psychiatry research leads to prestigious science prize
13. October 2020
Christian Sandøe Musaeus Lundbeckfonden
Concentrating on Dementia
13. October 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge